Search results
Showing 2656 to 2670 of 8930 results
Empagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
Canagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
Dapagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
Awaiting development Reference number: GID-TA11968 Expected publication date: TBC
In development Reference number: GID-TA10239 Expected publication date: 06 August 2026
Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making
Antimicrobial prescribing: meropenem with vaborbactam (ES21)
Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making
Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis
Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)
Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam